• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Press Media Release

press release distribution

  • Sponsored Post
  • Market Wire
  • About
    • Template for press/media release
    • How to structure your press release for maximum impact
    • Crafting effective headlines and leads to capture journalists’ attention
    • Understanding the dos and don’ts of writing press releases
    • Tips for writing clear, concise, and informative press releases
    • The importance of understanding your audience before writing a press release
    • Best practices for incorporating quotes and statistics in your press release
    • Writing effective boilerplates and about us sections for press releases
    • Identifying key media contacts and building relationships with journalists
    • Writing for different types of media, such as print, online, and social media
    • Measuring the success of your press release and tracking media coverage
  • Contact
    • GDPR

First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response

December 19, 2019 By admin

The U.S. Food and Drug Administration announced today the approval of Ervebo, the first FDA-approved vaccine for the prevention of Ebola virus disease (EVD), caused by Zaire ebolavirus in individuals 18 years of age and older. Cases of EVD are very rare in the U.S., and those that have occurred have been the result of infections acquired by individuals in other countries who then traveled to the U.S., or health care workers who became ill after treating patients with EVD.

“While the risk of Ebola virus disease in the U.S. remains low, the U.S. government remains deeply committed to fighting devastating Ebola outbreaks in Africa, including the current outbreak in the Democratic Republic of the Congo,” said Anna Abram, FDA Deputy Commissioner for Policy, Legislation, and International Affairs. “Today’s approval is an important step in our continuing efforts to fight Ebola in close coordination with our partners across the U.S. Department of Health and Human Services, as well as our international partners, such as the World Health Organization. These efforts, including today’s landmark approval, reflect the FDA’s unwavering dedication to leveraging our expertise to facilitate the development and availability of safe and effective medical products to address urgent public health needs and fight infectious diseases, as part of our vital public health mission.”

EVD is contagious and is transmitted through direct contact with blood, body fluids and tissues of infected wild animals or people, as well as with surfaces and materials, such as bedding and clothing, contaminated with these fluids. Onset of symptoms of EVD can be sudden and can include fever, fatigue, muscle pain, headache and sore throat. This is followed by vomiting, diarrhea, rash, impaired kidney and liver function and in some cases internal and external bleeding. EVD has an incubation period that ranges from 2 to 21 days. Individuals who provide care for people with EVD, including health care workers who do not use correct infection control precautions, are at the highest risk for infection.

Confirmed outbreaks of EVD have been documented since the 1970s, primarily in areas of sub-Saharan Africa, where scientists believe the virus is always present at low levels in certain infected wild animals. On rare occasions, people become sick with EVD after coming into direct contact with infected animals, which can then lead to EVD outbreaks when the virus spreads between people.
An outbreak in three West African countries (Guinea, Liberia and Sierra Leone) from 2014 to 2016 resulted in more than 28,000 cases of EVD and more than 11,000 deaths that were caused by Zaire ebolavirus.

The Democratic Republic of the Congo (DRC) is currently experiencing the world’s second largest EVD outbreak. In 2018, the World Health Organization (WHO) and the DRC began to use Ervebo as an investigational vaccine under an expanded access program to help mitigate this outbreak. With or without vaccination, it is critical to implement appropriate infection control and prevention measures as part of efforts to prevent the spread of EVD.

“Ebola virus disease is a rare but severe and often deadly disease that knows no borders. Vaccination is essential to help prevent outbreaks and to stop the Ebola virus from spreading when outbreaks do occur,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “The FDA’s approval of Ervebo is a major advance in helping to protect against the Zaire ebolavirus as well as advancing U.S. government preparedness efforts. The research approach used to study the effectiveness and safety of this vaccine was precedent-setting during a public health emergency and may help create a model for future studies under similar circumstances. The FDA is committed to continuing our work across the U.S. government and with our international partners to prevent future Ebola outbreaks and mitigate the current outbreak in the DRC, reflecting our nation’s commitment to preparing for and responding to biological threats, like Ebola.”

The approval of Ervebo is supported by a study conducted in Guinea during the 2014-2016 outbreak in individuals 18 years of age and older. The study was a randomized cluster (ring) vaccination study in which 3,537 contacts and contacts of contacts of individuals with laboratory-confirmed EVD received either “immediate” or 21-day “delayed” vaccination with Ervebo. This noteworthy design was intended to capture a social network of individuals and locations that might include dwellings or workplaces where a patient spent time while symptomatic, or the households of individuals who had contact with the patient during that person’s illness or death. In a comparison of cases of EVD among 2,108 individuals in the “immediate” vaccination arm and 1,429 individuals in the “delayed” vaccination arm, Ervebo was determined to be 100% effective in preventing Ebola cases with symptom onset greater than 10 days after vaccination. No cases of EVD with symptom onset greater than 10 days after vaccination were observed in the “immediate” cluster group, compared with 10 cases of EVD in the 21-day “delayed” cluster group.

In additional studies, antibody responses to Ervebo were assessed in 477 individuals in Liberia, approximately 500 individuals in Sierra Leone and approximately 900 individuals in Canada, Spain and the U.S. The antibody responses among those in the study conducted in Canada, Spain and the U.S. were similar to those among individuals in the studies conducted in Liberia and Sierra Leone.

The safety of Ervebo was assessed in approximately 15,000 individuals in Africa, Europe and North America. The most commonly reported side effects were pain, swelling and redness at the injection site, as well as headache, fever, joint and muscle aches and fatigue.

Ervebo is administered as a single-dose injection, and is a live, attenuated vaccine that has been genetically engineered to contain a protein from the Zaire ebolavirus.

The FDA granted this application Priority Review and a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases. The FDA also granted Breakthrough Therapy designation for Ervebo to facilitate the development and scientific evaluation of the vaccine. Because of the public health importance of a vaccine to prevent EVD, the FDA worked closely with the company and completed its evaluation of the safety and effectiveness of Ervebo in less than six months.

The approval was granted to Merck & Co., Inc.

Source: FDA

Filed Under: Press Release Tagged With: Ebola, Ebola vaccine, Ebola virus, Ebola virus disease

Footer

Recent Posts

  • Quectel Launches SP900BF-AP Edge AI Module With 100 TOPS and Ten 5G Combo Antennas at electronica 2026
  • Drax, Brookfield and Radiant Announce a 20 Billion Pound AI Data Centre With No Tenant, No Power Price and No Planning Consent Yet
  • Deal Releases November 5 2026 GE HealthCare Leads Up to 160 Million Dollars for Laza Medical and Priority Software Buys Fireberry
  • Tech Press Release Digest November 5 2026 Renesas Puts a Robot Controller on One Chip and Mirth Connect 4.8 Ships
  • A. O. Smith Sells 81 Percent of Its China Business to CPE at a Valuation Below One Year of Sales
  • Tokening, EByte, and Posterial Give Recent Project Updates Somewhere Useful to Lead
  • Press Releases Need Evidence Beyond a Strong Headline
  • School Communications Become an Enrollment Strategy, With AI Joining the Toolkit
  • Tech Press Release Digest: Record $425B Chip Quarter, Claude for Financial Advisors and Temporal’s $550M Raise
  • Japan Lost Its Export Lead to South Korea and Taiwan. AI Chips Explain Almost All of It

Media Partners

  • Press Club US
  • ZGM.org
  • Referently.com
Czech Television and Czech Radio Strike for a Day as Babiš Moves Public Media Onto the State Budget
Trump Says He May Move the White House Press Corps Out of the Brady Briefing Room
CrossGov.com Gives Reporters Covering Washington a Ready Story List: Tariff Refunds, a Shrinking CISA, FEMA Denials and an IRS With No Commissioner
Why Social Unrest Has Become a Standing Condition in Europe and the United States
UN Secretary-General Race: Rodrigues Birkett Takes the Lead While Grossi Collects Discourage Votes
Eight Pulitzer Winners and Finalists Used AI in Their 2026 Work
BuzzFeed and GB News Cut a Third of Staff Each as 2026 Job Losses Pile Up
Hormuz Talks Stall, Samsung Stacks Memory on the GPU, Taiwan Slows Its Own Networks: August 10 Briefing
Trump Administration Clears Saudi Nuclear Deal Without Enrichment Safeguards
Lindsey Graham, South Carolina Senator and Foreign Policy Hawk, Dies at 71
The Legend of Zelda Ocarina of Time Remake Sells Over 5 Million on Switch 2 in Four Days as Nintendo Builds Toward the 2027 Film
Hackers Turned Supermarket Freezers Into Heaters Across Europe and the Weak Point Was the Remote Maintenance Link
Tablet Shipments Fall 23 Percent to 32 Million in Q3 2026 and Only Lenovo Grows Among the Top Five
Vertiv Packages AI Rack Power and Cooling for Existing Facilities
Posterial, HomePremise, and RefurbishedContainers Turn Visual Concepts Into Editorial Projects
CrossGov.com Reads Washington for Market Signals: Section 232 Tariffs, Data Centre Grid Fights, LNG Approvals and a 4% Fed
Mid-September Across the Network: Chokepoints, Memory Prices, and the Crawler Block Landing September 15
YouTube's Creator Partnerships API Turns Influencer Deals Into Programmatic Media Buys
Scripps Cuts 268 Jobs and Rebuilds Local TV News Around Automation
Singapore's GDP Upgrade and CoreWeave's $104 Billion Backlog: The AI Boom Has Reached the Lagging Indicators
Isolated Gate Driver Explained, What It Does in Inverters, Chargers and Motor Drives
Cohort Stock Decline Explained, Why Themed Stocks Fall Together and When the Selling Ends
Force Majeure
Why Database Indexes Make Some Queries Faster and Writes More Expensive
High-Frequency Trading Explained: Speed, Strategies and the Structure of Modern Markets
Stirling Engines Explained From Working Gas to Useful Power
CoWoS Explained: TSMC's Advanced Packaging and Why It Bottlenecks AI Chips
Stock Market Circuit Breakers Explained: Market-Wide Halts, LULD Bands and Single-Stock Pauses
Short Interest Explained: Days to Cover, Percent of Float and How Short Squeezes Start
Rare Earth Magnet Supply Chain Explained: Mining, Separation, NdFeB Magnets and China's Hold on Each Step

Media Partners

  • Media Presser
  • 3V.org
  • k4i.com
Pulley Raises 64 Million Dollars as Permitting Delays Hold Back Construction
MarketAnalysis Digest, November 18 2026, Nvidia Margins, AI Export Controls and Hormuz Risk
Omdia Counts a 23% Drop in Q3 2026 Tablet Shipments as Lenovo Finds Only 10% of IT Leaders Rebuilt the Workplace for AI
Nielsen Prices 1.4 Billion Dollars of 10.5 Percent Notes to Pay for DoubleVerify and Puts Ad Verification on Private Equity Debt
Bank of England, Czech National Bank and Bank of Canada Raise Rates as an Energy Shock Feeds Inflation
Media Earnings November 5 2026 Nexstar Posts a Record 2.1 Billion Dollars and IMAX Nearly Doubles Its Box Office Record
FuriosaAI, Serval and Solink Lead Over a Billion Dollars of AI Funding in One Day
News Embargoes Break Because the Incentives Do, and the Fix Is Fewer Embargoes
RenderCache, EByte, and Selectivity Expose the Limits Behind a Successful Software Result
Q3 2026 Bank Earnings Show Net Interest Income Growing Again Just as the Fed Turns to Hikes
Torus Raises $500 Million to Put AI Inference Next to Spare Grid Capacity With Foundry
OpenAI Banks 11 Billion Dollars at a Trillion-Plus Valuation After Cutting Its Round From 30 Billion to 20
Deal Digest November 5 2026 Five9 Pays 325 Million Dollars for Level AI and MasTec Drops a Deal to Buy Back Stock
Deal Digest October 29 2026 DoorDash Buys Instacart for 17 Billion Dollars and Xerox Pays More to Owe Less
SK Hynix Says Memory Stays Short Through 2030 as Long-Term Contracts Cover Over Half of 2027 Capacity
Tokening, RenderCache, and Selectivity Make Software Claims Easier to Inspect
Quantum Art Wave Simulation Claim Raises the Question of What a Quantum Result Actually Delivers
AI Infrastructure Financing Digest October 22 2026 Shows Short Debt Funding Long Bets
CrossGov's Overlooked Federal Numbers: $13.5 Million Saved on $1 Billion, a 14% Sustain Rate and a 60-Year-Old System Still Running
Press Release Digest: Rubrik Puts Claude Mythos 5 on Code Security, Factory Hits $5 Billion, TeRAM Takes On the AI Memory Wall
Vicor Fiscal 2025 10-K Adds New AI Demand Risk
OFAC Adds 24 Names to the SDN List in Narcotics and Organized Crime and Cyber Actions, November 19, 2026
China Commerce Ministry Reports Stable Double Eleven Consumption Trends
BIS Export Control Rule, Addressing Remote Access to Advanced Semiconductors, November 19, 2026
OFAC Adds 6 Names to the SDN List in Counterterrorism Actions, November 18, 2026
South Korea Policy Briefing Posts Outline Content Restrictions
Lumentum Fiscal 2026 10-K Adds New Intellectual Property Risks
Insider Trades at Chip and AI Infrastructure Companies, November 18, 2026
CISA Adds 4 Exploited Vulnerabilities in Synology, BerriAI and Others Products, November 18, 2026
NVIDIA Guides Fiscal Q4 2027 Revenue to $130 Billion, Up 12 Percent From Fiscal Q3 2027

Copyright © 2026 PressMediaRelease.com

Media Partners: Technologies · Market Analysis · Market Research · Photography · Media Presser · 3V · Briefly · ESN